Spero Therapeutics Inc (SPRO)
1.24
-0.07
(-5.34%)
USD |
NASDAQ |
Nov 14, 12:52
Spero Therapeutics Net Income (Quarterly): -17.86M for June 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | -17.86M |
March 31, 2024 | -12.67M |
December 31, 2023 | 51.19M |
September 30, 2023 | -3.205M |
June 30, 2023 | -11.91M |
March 31, 2023 | -13.27M |
December 31, 2022 | 26.77M |
September 30, 2022 | -11.68M |
June 30, 2022 | -28.68M |
March 31, 2022 | -32.83M |
December 31, 2021 | -29.24M |
September 30, 2021 | -22.52M |
June 30, 2021 | -18.57M |
March 31, 2021 | -19.42M |
December 31, 2020 | -18.58M |
September 30, 2020 | -18.94M |
Date | Value |
---|---|
June 30, 2020 | -17.50M |
March 31, 2020 | -23.26M |
December 31, 2019 | -24.99M |
September 30, 2019 | -17.72M |
June 30, 2019 | -13.15M |
March 31, 2019 | -5.072M |
December 31, 2018 | -10.60M |
September 30, 2018 | -10.46M |
June 30, 2018 | -9.956M |
March 31, 2018 | -10.64M |
December 31, 2017 | -13.86M |
September 30, 2017 | -9.836M |
June 30, 2017 | -9.169M |
March 31, 2017 | -5.876M |
December 31, 2016 | -7.211M |
September 30, 2016 | -6.316M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-32.83M
Minimum
Mar 2022
51.19M
Maximum
Dec 2023
-13.01M
Average
-18.57M
Median
Jun 2021
Net Income (Quarterly) Benchmarks
Arbutus Biopharma Corp | -19.72M |
Equillium Inc | 0.468M |
NovaBay Pharmaceuticals Inc | -1.585M |
Palatin Technologies Inc | -8.250M |
iBio Inc | -7.778M |
Net Income (Quarterly) Related Metrics
Revenue (Quarterly) | 6.017M |
Total Expenses (Quarterly) | 25.08M |
EPS Diluted (Quarterly) | -0.33 |
Enterprise Value | 7.277M |
Profit Margin (Quarterly) | -296.9% |
Earnings Yield | 27.42% |
Operating Earnings Yield | 31.40% |
Normalized Earnings Yield | 33.83 |